The archaic distinction between functioning and nonfunctioning neuroendocrine neoplasms is no longer clinically relevant

Langenbeck's Archives of Surgery

Volumn 396, Issue 8, 2011, Pages 1145-1156

  Modlin, Irvin M ^a   Moss, Steven F ^b   Gustafsson, Bjorn I ^c   Lawrence, Ben ^a   Schimmack, Simon ^a,d   Kidd, Mark ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BROWN UNIVERSITY   (United States)

^c NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^d UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Carcinoid; Epidemiology; Functional; Incidence; Nonfunctional; Pancreatic neuroendocrine tumor; SEER; Survival

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BIOCHEMICAL MARKER; CAPECITABINE; CARBOPLATIN; CYTOTOXIC AGENT; DOXORUBICIN; ETOPOSIDE; EVEROLIMUS; FLUOROURACIL; LONG ACTING DRUG; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; OCTREOTIDE; PROTEIN TYROSINE KINASE INHIBITOR; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; STREPTOZOCIN; SUNITINIB; SYNAPTOPHYSIN; TEMOZOLOMIDE; THALIDOMIDE; VASCULOTROPIN INHIBITOR;

ABLATION THERAPY; ADVANCED CANCER; BIOLOGICAL THERAPY; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER GENETICS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARCINOID; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; DIAGNOSTIC IMAGING; DRUG EFFICACY; ENDOSCOPIC ECHOGRAPHY; EVIDENCE BASED MEDICINE; GENE EXPRESSION REGULATION; GENE MUTATION; HUMAN; INTESTINE TUMOR; LIVER TRANSPLANTATION; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS CANCER; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RADIOISOTOPE THERAPY; SCINTIGRAPHY; SYSTEMIC THERAPY;

BIOPSY, NEEDLE; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; NEOPLASM STAGING; NEUROENDOCRINE TUMORS; PROGNOSIS; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 82255191962     PISSN: 14352443     EISSN: 14352451     Source Type: Journal    
DOI: 10.1007/s00423-011-0794-7     Document Type: Conference Paper

References (84)

1. IM Modlin K Oberg DC Chung, et al. 2008 The current status of gastroenteropancreatic neuroendocrine tumors Lancet Oncol 9 61 72 18177818 10.1016/S1470-2045(07)70410-2 1:CAS:528:DC%2BD1cXivVOltQ%3D%3D
2. JC Yao M Hassan A Phan 2008 One hundred years after "carcinoid" : epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States J Clin Oncol 26 18 3063 3072 18565894 10.1200/JCO.2007.15.4377
3. IM Modlin SF Moss DC Chung RT Jensen E Snyderwine 2008 Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors J Natl Cancer Inst 100 18 1282 1289 18780869 10.1093/jnci/djn275
4. S Schimmack B Svejda B Lawrence M Kidd I Modlin 2011 The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors Langenbeck's Archives 396 3 273 298 10.1007/s00423-011-0739-1
5. RB Kent 3rd JA van Heerden LH Weiland 1981 Nonfunctioning islet cell tumors Ann Surg 193 2 185 190 6258500 10.1097/00000658-198102000-00010 (Pubitemid 11153101)
6. N Nomura T Fujii N Kanazumi, et al. 2009 Nonfunctioning neuroendocrine pancreatic tumors: our experience and management J Hepatobiliary Pancreat Surg 16 5 639 647 19365596 10.1007/s00534-009-0099-1
7. B Lawrence B Gustafsson A Chan B Svejda M Kidd I Modlin 2010 The epidemiology of gastroenteropancreatic tumors Endocrinol Metab Clin North Am 40 1 1 18 10.1016/j.ecl.2010.12.005
8. J Franko W Feng L Yip E Genovese AJ Moser 2010 Non-functional neuroendocrine carcinoma of the pancreas: incidence, tumor biology, and outcomes in 2,158 patients J Gastrointest Surg 14 3 541 548 19997980 10.1007/s11605-009-1115-0
9. TP Chung SR Hunt 2006 Carcinoid and neuroendocrine tumors of the colon and rectum Clin Colon Rectal Surg 19 2 45 48 20011309 10.1055/s-2006-942343 (Pubitemid 43855634)
10. MW Onaitis PM Kirshbom TZ Hayward, et al. 2000 Gastrointestinal carcinoids: characterization by site of origin and hormone production Ann Surg 232 4 549 556 10998653 10.1097/00000658-200010000-00010 1:STN:280: DC%2BD3M%2Fhs1eiuw%3D%3D
11. O Soreide T Berstad A Bakka, et al. 1992 Surgical treatment as a principle in patients with advanced abdominal carcinoid tumors Surgery 111 1 48 54 1728075 1:STN:280:DyaK38%2FpsVGjtA%3D%3D
12. UF Pape M Bohmig U Berndt N Tiling B Wiedenmann U Plockinger 2004 Survival and clinical outcome of patients with neuroendocrine tumors of the gastroenteropancreatic tract in a german referral center Ann NY Acad Sci 1014 222 233 15153439 10.1196/annals.1294.025 (Pubitemid 38594810)
13. S Ekeblad B Skogseid K Dunder K Oberg B Eriksson 2008 Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution Clin Cancer Res 14 23 7798 7803 19047107 10.1158/1078-0432.CCR-08- 0734 1:CAS:528:DC%2BD1cXhsVegtrfJ
14. A Zerbi M Falconi G Rindi, et al. 2010 Clinicopathological features of pancreatic endocrine tumors: a prospective multicenter study in Italy of 297 sporadic cases Am J Gastroenterol 105 6 1421 1429 20087335 10.1038/ajg.2009.747
15. LE Broder SK Carter 1973 Pancreatic islet cell carcinoma. I. Clinical features of 52 patients Ann Intern Med 79 1 101 107 4352783 1:STN:280: DyaE3s3isF2qtQ%3D%3D
16. IM Modlin BI Gustafsson SF Moss M Pavel AV Tsolakis M Kidd 2010 Chromogranin A-biological function and clinical utility in neuro endocrine tumor disease Ann Surg Oncol 17 9 2427 2443 20217257 10.1245/s10434-010-1006-3
17. Oberndorfer S. Karzinoide tumores des Dunndarms. Frankf Z Pathol. 1907:426-443
18. DeLellis RA, Lloyd RV, Heitz PU, Eng C (eds) (2004) World Health Organization classification of tumours, pathology and genetics of tumours of endocrine organs. IARC, Lyon
19. U Plockinger G Rindi R Arnold, et al. 2004 Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS) Neuroendocrinology 80 6 394 424 15838182 10.1159/000085237 1:STN:280: DC%2BD2M3nt1Chtw%3D%3D (Pubitemid 40874886)
20. Bosman F, Carneiro F, Hruban R, Theise N (2010) WHO classification of tumours of the digestive system. WHO/IARC, Lyon
21. DS Klimstra IM Modlin NV Adsay, et al. 2010 Pathologic reporting of neuroendocrine tumors: Application of the Delphic consensus process to the development of a minimum pathologic data set Am J Surg Pathol 34 3 300 313 20118772 10.1097/PAS.0b013e3181ce1447
22. DC Metz 1999 Diagnosis of non-Zollinger-Ellison syndrome, non-carcinoid syndrome, enteropancreatic neuroendocrine tumours Ital J Gastroenterol Hepatol 31 Suppl 2 S153 S159 10604121 (Pubitemid 29527886)
23. K Oberg B Skogseid 1998 The ultimate biochemical diagnosis of endocrine pancreatic tumours in MEN-1 J Intern Med 243 6 471 476 9681845 10.1046/j.1365-2796.1998.00280.x 1:CAS:528:DyaK1cXks1Wktbc%3D (Pubitemid 28312243)
24. M Stivanello A Berruti M Torta 2001 Circulating chromogranin A in the assessment of patients with neuroendocrine tumours. A single institution experience Ann Oncol 12 Suppl 2 S73 S77 11762356 10.1023/A:1012490206760
25. K Oberg B Eriksson 2005 Endocrine tumours of the pancreas Best Pract Res Clin Gastroenterol 19 5 753 781 16253899 10.1016/j.bpg.2005.06.002 (Pubitemid 41614122)
26. RT Jensen B Niederle E Mitry, et al. 2006 Gastrinoma (duodenal and pancreatic) Neuroendocrinology 84 3 173 182 17312377 10.1159/000098009 1:CAS:528:DC%2BD2sXhvFSmtrY%3D (Pubitemid 46361051)
27. J Zhao H Moch AF Scheidweiler, et al. 2001 Genomic imbalances in the progression of endocrine pancreatic tumors Genes Chromosom Cancer 32 4 364 372 11746977 10.1002/gcc.1201 1:CAS:528:DC%2BD3MXovVKgurY%3D (Pubitemid 33055121)
28. MA Forget S Turcotte D Beauseigle 2007 The Wnt pathway regulator DKK1 is preferentially expressed in hormone-resistant breast tumours and in some common cancer types Br J Cancer 96 4 646 653 17245340 10.1038/sj.bjc.6603579 1:CAS:528:DC%2BD2sXhvV2jtr4%3D
29. JM Gonzalez-Sancho O Aguilera JM Garcia, et al. 2005 The Wnt antagonist DICKKOPF-1 gene is a downstream target of beta-catenin/TCF and is downregulated in human colon cancer Oncogene 24 6 1098 1103 15592505 10.1038/sj.onc.1208303 1:CAS:528:DC%2BD2MXptlKgtg%3D%3D (Pubitemid 40313887)
30. TA Johansson G Westin B Skogseid 2009 Identification of Achaete-scute complex-like 1 (ASCL1) target genes and evaluation of DKK1 and TPH1 expression in pancreatic endocrine tumours BMC Cancer 9 321 19744316 10.1186/1471-2407-9- 321
31. Y Jiao C Shi BH Edil, et al. 2011 DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors Science 331 6021 1199 203 21252315 10.1126/science.1200609 1:CAS:528:DC%2BC3MXislOku70%3D
32. G Floridia G Grilli M Salvatore, et al. 2005 Chromosomal alterations detected by comparative genomic hybridization in nonfunctioning endocrine pancreatic tumors Cancer Genet Cytogenet 156 1 23 30 15588852 10.1016/j.cancergencyto.2004.04.015 1:CAS:528:DC%2BD2cXhtVKksL3P (Pubitemid 39601055)
33. G Rigaud E Missiaglia PS Moore, et al. 2001 High resolution allelotype of nonfunctional pancreatic endocrine tumors: identification of two molecular subgroups with clinical implications Cancer Res 61 1 285 292 11196176 1:CAS:528:DC%2BD3MXlsl2rtA%3D%3D (Pubitemid 32095729)
34. PK Woodard JM Feldman SS Paine ME Baker 1995 Midgut carcinoid tumors: CT findings and biochemical profiles J Comput Assist Tomogr 19 3 400 405 7540631 10.1097/00004728-199505000-00012 1:STN:280:DyaK2MzhtVGmtw%3D%3D
35. GA Kaltsas GM Besser AB Grossman 2004 The diagnosis and medical management of advanced neuroendocrine tumors Endocr Rev 25 3 458 511 15180952 10.1210/er.2003-0014 1:CAS:528:DC%2BD2cXlvVeltLs%3D (Pubitemid 38780668)
36. N Garbrecht M Anlauf A Schmitt, et al. 2008 Somatostatin-producing neuroendocrine tumors of the duodenum and pancreas: incidence, types, biological behavior, association with inherited syndromes, and functional activity Endocr Relat Cancer 15 1 229 241 18310290 10.1677/ERC-07-0157 (Pubitemid 351449742)
37. A Rinke HH Muller C Schade-Brittinger, et al. 2009 Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group J Clin Oncol 27 4656 4663 19704057 10.1200/JCO.2009.22.8510 1:CAS:528:DC%2BD1MXhtlGgtbnJ
38. AK Ganti WW West RP Lackner A Kessinger 2010 Current concepts in the diagnosis and management of small-cell lung cancer Oncology (Williston Park) 24 11 1034 1039
39. M Stridsberg K Oberg Q Li, et al. 1995 Measurement of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours J Endocrinol 144 49 59 7891024 10.1677/joe.0. 1440049 1:CAS:528:DyaK2MXjtlCktL4%3D
40. O Rorstad 2005 Prognostic indicators for carcinoid neuroendocrine tumors of the gastrointestinal tract J Surg Oncol 89 151 160 15719376 10.1002/jso.20179 (Pubitemid 40315912)
41. M Stridsberg B Eriksson K Oberg ET Janson 2003 A comparison between three commercial kits for chromogranin A measurements J Endocrinol 177 2 337 341 12740022 10.1677/joe.0.1770337 1:CAS:528:DC%2BD3sXktlyntbY%3D (Pubitemid 36656407)
42. F Panzuto C Severi R Cannizzaro, et al. 2004 Utility of combined use of plasma levels of chromogranin A and pancreatic polypeptide in the diagnosis of gastrointestinal and pancreatic endocrine tumors J Endocrinol Investig 27 1 6 11 1:CAS:528:DC%2BD2cXivVCjtb0%3D (Pubitemid 38324712)
43. GC Nikou K Marinou P Thomakos, et al. 2008 Chromogranin a levels in diagnosis, treatment and follow-up of 42 patients with non-functioning pancreatic endocrine tumours Pancreatology 8 4-5 510 519 18765956 10.1159/000152000 1:CAS:528:DC%2BD1cXhtFyqtr3M
44. TJ Wu CL Lin RL Taylor LK Kvols PC Kao 1997 Increased parathyroid hormone-related peptide in patients with hypercalcemia associated with islet cell carcinoma Mayo Clin Proc 72 12 1111 1115 9413289 10.4065/72.12.1111 1:STN:280:DyaK1c%2FnsFaisg%3D%3D (Pubitemid 27528320)
45. S Corbetta M Peracchi V Cappiello, et al. 2003 Circulating ghrelin levels in patients with pancreatic and gastrointestinal neuroendocrine tumors: identification of one pancreatic ghrelinoma J Clin Endocrinol Metab 88 7 3117 3120 12843152 10.1210/jc.2002-021842 1:CAS:528:DC%2BD3sXlslaitrs%3D (Pubitemid 36877481)
46. IM Modlin M Kidd I Latich MN Zikusoka MD Shapiro 2005 Current status of gastrointestinal carcinoids Gastroenterology 128 6 1717 1751 15887161 10.1053/j.gastro.2005.03.038 (Pubitemid 40692562)
47. SV Murugesan A Varro DM Pritchard 2009 Review article: strategies to determine whether hypergastrinaemia is due to Zollinger-Ellison syndrome rather than a more common benign cause Aliment Pharmacol Ther 29 10 1055 1068 19226290 10.1111/j.1365-2036.2009.03976.x 1:CAS:528:DC%2BD1MXmtVOltrc%3D
48. J Marko R Lamba F Miller A Buchman S Spies P Nikolaidis 2008 OctreoScan positive Crohn's disease mimicking an ileal carcinoid tumor J Clin Gastroenterol 42 1 66 68 18097293 10.1097/01.mcg.0000212640.52359.ca
49. M Hofmann H Maecke R Borner, et al. 2001 Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data Eur J Nucl Med 28 12 1751 1757 11734911 10.1007/s002590100639 1:CAS:528: DC%2BD3MXosFagurs%3D
50. M Papotti M Bongiovanni M Volante, et al. 2002 Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis Virchows Arch 440 5 461 475 12021920 10.1007/s00428-002-0609-x 1:CAS:528:DC%2BD38Xjs1yhsLc%3D (Pubitemid 34591729)
51. E Missiaglia I Dalai S Barbi, et al. 2010 Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway J Clin Oncol 28 2 245 255 19917848 10.1200/JCO.2008.21.5988 1:CAS:528:DC%2BC3cXjtVSqt7c%3D
52. N Kimura M Pilichowska F Date I Kimura M Schindler 1999 Immunohistochemical expression of somatostatin type 2A receptor in neuroendocrine tumors Clin Cancer Res 5 11 3483 3487 10589762 1:CAS:528:DyaK1MXotV2gsb0%3D
53. H Kulaksiz R Eissele D Rossler, et al. 2002 Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumours with subtype specific antibodies Gut 50 1 52 60 11772967 10.1136/gut.50.1.52 1:CAS:528:DC%2BD38XltVOrug%3D%3D (Pubitemid 34028303)
54. ML Fjallskog E Ludvigsen M Stridsberg K Oberg B Eriksson ET Janson 2003 Expression of somatostatin receptor subtypes 1 to 5 in tumor tissue and intratumoral vessels in malignant endocrine pancreatic tumors Med Oncol 20 1 59 67 12665686 10.1385/MO:20:1:59 (Pubitemid 36344027)
55. VD Corleto M Falconi F Panzuto, et al. 2009 Somatostatin receptor subtypes 2 and 5 are associated with better survival in well-differentiated endocrine carcinomas Neuroendocrinology 89 2 223 230 18974627 10.1159/000167796 1:CAS:528:DC%2BD1MXisFSqsro%3D
56. SA Pais M Al-Haddad M Mehdi, et al. 2010 EUS for pancreatic neuroendocrine tumors: a single-center, 11-year experience Gastrointest Endosc 71 7 1185 1193 20304401 10.1016/j.gie.2009.12.006
57. JA Norton DL Fraker HR Alexander, et al. 2006 Surgery increases survival in patients with gastrinoma Ann Surg 244 3 410 419 16926567
58. RS Chamberlain D Canes KT Brown, et al. 2000 Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg 190 4 432 445 10757381 10.1016/S1072-7515(00)00222-2 1:STN:280:DC%2BD3c3hvVejtQ%3D%3D (Pubitemid 30181109)
59. D O'Toole P Ruszniewski 2005 Chemoembolization and other ablative therapies for liver metastases of gastrointestinal endocrine tumours Best Pract Res Clin Gastroenterol 19 4 585 594 16183529 10.1016/j.bpg.2005.02.011 (Pubitemid 41447720)
60. D O'Toole F Maire P Ruszniewski 2003 Ablative therapies for liver metastases of digestive endocrine tumours Endocr Relat Cancer 10 4 463 468 14713259 10.1677/erc.0.0100463 (Pubitemid 38094883)
61. FG van Vilsteren ES Baskin-Bey DM Nagorney, et al. 2006 Liver transplantation for gastroenteropancreatic neuroendocrine cancers: Defining selection criteria to improve survival Liver Transpl 12 3 448 456 16498656 10.1002/lt.20702
62. I Modlin M Pavel M Kidd B Gustafsson 2010 Somatostatin analogues: an appraisal of their utility and efficacy Aliment Pharmacol Ther 31 2 169 188 19845567 1:CAS:528:DC%2BC3cXhtlOgs7c%3D
63. MH Kulke JL Hornick C Frauenhoffer, et al. 2009 O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors Clin Cancer Res 15 1 338 345 19118063 10.1158/1078-0432.CCR-08-1476 1:CAS:528:DC%2BD1MXhs1eqsQ%3D%3D
64. ET Janson H Sorbye S Welin, et al. 2010 Nordic Guidelines 2010 for diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours Acta Oncol 49 6 740 756 20553100 10.3109/0284186X.2010.492791 1:CAS:528: DC%2BC3cXos1KjsLs%3D
65. MH Kulke 2007 Clinical presentation and management of carcinoid tumors Hematol Oncol Clin North Am 21 3 433 455 17548033 10.1016/j.hoc.2007.04.004 vii-viii (Pubitemid 46843513)
66. CG Moertel LK Kvols MJ O'Connell J Rubin 1991 Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms Cancer 68 2 227 232 1712661 10.1002/1097-0142(19910715)68:2<227::AID-CNCR2820680202>3.0.CO;2-I 1:STN:280:DyaK3MzgtVCjuw%3D%3D
67. IM Modlin M Kidd I Drozdov ZL Siddique BI Gustafsson 2008 Pharmacotherapy of neuroendocrine cancers Expert Opin Pharmacother 9 15 2617 2626 18803449 10.1517/14656566.9.15.2617 1:CAS:528:DC%2BD1cXhtFegtL%2FJ
68. Pavel M, Hainsworth JD, Baudin E, et al. (2010) A randomized, double-blind, placebo-controlled, multicenter phase III trial of everolimus∈+∈octreotide lar vs placebo∈+∈octreotide LAR in patients with advanced neuroendocrine tumors (NET) (RADIANT-2). Ann Oncol 21(Suppl 8):Abst LBA8
69. Yao JC, Shah MH, Ito T, et al. (2010) A randomized, double-blind, placebo-controlled, multicenter phase iii trial of everolimus in patients with advanced pancreatic neuroendocrine tumors (PNET) (RADIANT-3). Ann Oncol 21(Suppl 8):Abst LBA9
70. Kulke M, Blaszkowsky L, Zhu A, Flortio S, Regan E (2010 ) Phase I/II study of everolimus (RAD001) in combination with Temozolamide (TMZ) in patients (pts) with advanced pancreatic neuroendocrine tumors (NET). Proc Am Soc Clin Oncol Gast Int:Abstr 223
71. MH Kulke K Stuart PC Enzinger, et al. 2006 Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors J Clin Oncol 24 3 401 406 16421420 10.1200/JCO.2005.03.6046 1:CAS:528:DC%2BD28XhsFSku70%3D (Pubitemid 46630459)
72. M van Essen EP Krenning BL Kam M de Jong R Valkema DJ Kwekkeboom 2009 Peptide-receptor radionuclide therapy for endocrine tumors Nat Rev Endocrinol 5 7 382 393 19488074 10.1038/nrendo.2009.105
73. A Scarpa W Mantovani P Capelli, et al. 2010 Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients Mod Pathol 23 6 824 833 20305616 10.1038/modpathol.2010.58 1:CAS:528:DC%2BC3cXmslSnsb4%3D
74. UF Pape H Jann J Muller-Nordhorn, et al. 2008 Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors Cancer 113 2 256 265 18506737 10.1002/cncr.23549
75. E Pomianowska IP Gladhaug K Grzyb, et al. 2010 Survival following resection of pancreatic endocrine tumors: importance of R-status and the WHO and TNM classification systems Scand J Gastroenterol 45 7-8 971 979 20441530 10.3109/00365521003782363
76. F Panzuto S Nasoni M Falconi, et al. 2005 Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization Endocr Relat Cancer 12 4 1083 1092 16322345 10.1677/erc.1.01017 (Pubitemid 41815799)
77. JC Yao MH Shah T Ito, et al. 2011 Everolimus for advanced pancreatic neuroendocrine tumors N Engl J Med 364 6 514 523 21306238 10.1056/NEJMoa1009290 1:CAS:528:DC%2BC3MXhvVyiu7s%3D
78. E Raymond L Dahan JL Raoul, et al. 2011 Sunitinib malate for the treatment of pancreatic neuroendocrine tumors N Engl J Med 364 6 501 513 21306237 10.1056/NEJMoa1003825 1:CAS:528:DC%2BC3MXhvVyisrY%3D
79. A Tanimoto Y Matsuki T Tomita T Sasaguri S Shimajiri Y Sasaguri 2004 Histidine decarboxylase expression in pancreatic endocrine cells and related tumors Pathol Int 54 6 408 412 15144399 10.1111/j.1440-1827.2004.01641.x 1:CAS:528:DC%2BD2cXls1OlurY%3D (Pubitemid 38829926)
80. C Bordi FP Pilato T D'Adda 1988 Comparative study of seven neuroendocrine markers in pancreatic endocrine tumours Virchows Arch A Pathol Anat Histopathol 413 5 387 398 2845642 10.1007/BF00716987 1:STN:280:DyaL1M%2FitVOrtA%3D%3D
81. RV Lloyd T Mervak K Schmidt TF Warner BS Wilson 1984 Immunohistochemical detection of chromogranin and neuron-specific enolase in pancreatic endocrine neoplasms Am J Surg Pathol 8 8 607 614 6205601 10.1097/00000478-198408000-00004 1:STN:280:DyaL2c3nvVWksg%3D%3D (Pubitemid 14055019)
82. G Chejfec S Falkmer L Grimelius, et al. 1987 Synaptophysin. A new marker for pancreatic neuroendocrine tumors Am J Surg Pathol Apr 11 4 241 247 10.1097/00000478-198704000-00001 1:STN:280:DyaL2s7ot1WksA%3D%3D (Pubitemid 17049073)
83. S Simpson AI Vinik PJ Marangos RV Lloyd 1984 Immunohistochemical localization of neuron-specific enolase in gastroenteropancreatic neuroendocrine tumors. Correlation with tissue and serum levels of neuron-specific enolase Cancer 54 7 1364 1369 6088026 10.1002/1097-0142(19841001)54:7<1364::AID- CNCR2820540722>3.0.CO;2-Y 1:STN:280:DyaL2c3ot1altQ%3D%3D (Pubitemid 14003536)
84. T Tomita JR Kimmel SR Friesen V Doull HG Pollock 1985 Pancreatic polypeptide in islet cell tumors. Morphologic and functional correlations Cancer 56 7 1649 1657 2992743 10.1002/1097-0142(19851001)56:7<1649::AID- CNCR2820560731>3.0.CO;2-3 1:STN:280:DyaL2M3ot1Sgsw%3D%3D (Pubitemid 15228517)